Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2007

Deal with Merck & Co. Could Be Worth over $700M to KineMed

  • KineMed has agreed to use its reverse cholesterol transport (RCT) technology to evaluate Merck & Co.’s investigational compounds. KineMed stands to earn up to $705.5 million based on various milestones.

    RCT is the only known metabolic pathway by which excess cholesterol can be removed from tissues, explain the companies. A relevant increase in the rate of RCT is the goal in raising HDL levels for the prevention and treatment of atherosclerosis.

    Under the terms of the agreement, KineMed could receive in excess of $5.5 million in initial and research payments should the collaboration extend for the full term. Merck will pay an additional $70 million in milestones for each of up to 10 compounds.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »